SEK tQ2 24/25Q2 23/24May-Oct 24/25May-Oct 23/24Full year 23/24Net sales2,3122,5634,0274,3167,290Operating profit (loss)-19,753-25,316-43,316-57,508-126,845Profit (loss) for ...

Figure 1. Cell Proliferation Assay of Linsitinib in both IGF-1R and TSH-R cell lines. In the IGF-1R cell line, inhibition ranged from 54 to 78% compared to control, while in the TSH-R cell line, ...

The liver breaks down dietary fructose into lipids that are used by cancer cells to boost their growth in mice.

In this manuscript, Yao et al. present solid evidence to show that MnMYL3 may serve as a receptor for NNV via macropinocytosis. This manuscript is valuable for understanding the molecular mechanisms ...

The European MCL Network Phase 3 TRIANGLE study, evaluated ibrutinib in combination with induction immunochemotherapy, both with and without an autologous stem cell transplant, followed by 24 months f ...

Now, with the cloning of its receptor and the generation of OX2 −/− mice, a possible role as an inhibitor for myeloid activation has emerged. The authors imply that CD200, acting through ...

This paper presents the important discovery that lipid metabolic imbalance caused by Snail, an EMT-related transcription factor, contributes to the acquisition of chemoresistance in cancer cells.

NEW YORK – Ideaya Biosciences said on Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.

Researchers present a new therapeutic tool capable of inhibiting the proliferation of the SARS-CoV-2 virus that causes COVID-19. The results open up new perspectives in the fight against this ...

In patients with renal insufficiency associated with increased hemoglobin levels and polycythemia, the possibilities of recombinant erythropoietin overdosing and disorders such as neoplasms and ...

Autoimmune bullous diseases are often associated with significant morbidity and some can even cause mortality, if left untreated. Multiple therapies are now available to treat these blistering ...

Interested in blogging for timesofindia.com? We will be happy to have you on board as a blogger, if you have the knack for writing. Just drop in a mail at [email protected] with a brief ...